Resistance to CCR5 Inhibitors in HIV-1: A Study on Coreceptor Switching
Author Information
Author(s): Nedellec Rebecca, Coetzer Mia, Lederman Michael M., Offord Robin E., Hartley Oliver, Mosier Donald E.
Primary Institution: The Scripps Research Institute
Hypothesis
Can HIV-1 develop resistance to the CCR5 inhibitor 5P12-RANTES through coreceptor switching to CXCR4?
Conclusion
The study found that resistance to the CCR5 inhibitor 5P12-RANTES requires a more complex evolution involving coreceptor switching to CXCR4, compared to resistance to the small molecule inhibitor maraviroc.
Supporting Evidence
- Resistance to maraviroc was achieved in 16-18 weeks with specific envelope mutations.
- Only transient resistance to 5P12-RANTES was observed, leading to virus replication collapse.
- Coreceptor switching to CXCR4 was necessary for sustained resistance to 5P12-RANTES.
Takeaway
HIV can change how it enters cells to avoid being stopped by medicines, and this change is harder to achieve with some medicines than others.
Methodology
The study involved in vitro selection experiments comparing the development of resistance to the small molecule inhibitor maraviroc and the macromolecular inhibitor 5P12-RANTES.
Limitations
The study was conducted in vitro, which may not fully replicate in vivo conditions.
Statistical Information
P-Value
p=0.0016
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website